查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
單純皰疹病毒治療市場：按類型、按藥物類型、按分銷渠道：全球機會分析和行業預測，2021-2031 年
市場調查報告書
商品編碼
1266411

單純皰疹病毒治療市場：按類型、按藥物類型、按分銷渠道：全球機會分析和行業預測，2021-2031 年

Herpes Simplex Virus Treatment Market By Type, By Drug type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 349 Pages | 商品交期: 2-3個工作天內

價格

2021 年單純皰疹病毒治療市場規模為 172427 萬美元，預計 2031 年將達到 212691 萬美元，從 2022 年到 2031 年的複合年增長率為 2.1%。

單純皰疹病毒 (HSV) 是一種常見的病毒感染，影響著全世界許多人。 單純皰疹病毒有兩種類型，1□□ 型 (HSV-1) 和 2 型 (HSV-2)。 HSV-1 通常與唇皰疹有關，唇皰疹會導致口腔周圍出現唇皰疹和熱水泡。 這種類型的皰疹在通過口交感染時也會引起生殖器皰疹。 HSV-2 是生殖器皰疹最常見的病因，但通過生殖器與口腔接觸感染時也會引起唇皰疹。 HSV 可以通過性接觸傳播，病毒也可以通過其他方式傳播。 單純皰疹病毒的治療包括抗病毒藥物、外用乳膏或軟膏以及控制症狀的家庭療法。 抗病毒藥物的使用在治療這種疾病方面顯示出可喜的結果。

單純皰疹病毒治療的全球市場受到皰疹病毒感染上升的顯著推動。 此外，與單純皰疹病毒相關的研發活動增加以及片劑和乳膏等新配方的開發預計將推動市場增長。 例如，德國生物製藥公司AiCuris Anti-infective Cures AG正在研發一種治療HSV感染的新型抗病毒藥物（Pritelivir）。 這種藥物“Pritelivir”是通過抑制病毒複製來發揮作用的，在臨床試驗中已經證實可以有效減少病毒脫落和感染頻率。 因此，單純皰疹病毒的研發活動十分活躍，推動了市場的增長。

另一方面，在欠發達國家，對性傳播感染 (STI) 和皰疹病毒等疾病的認識不足阻礙了市場增長。 然而，隨著對皰疹感染認識的提高，越來越多的人正在接受檢測和診斷。 這增加了發達國家對有效治療的需求。

此外，預計在預測期內，亞太地區和 LAMEA 地區新興經濟體的單純皰疹病毒藥物的開發和批准以及增長機會將推動市場增長。 例如，2020 年 11 月，Amneal Pharmaceuticals, LLC 宣布了縮寫 Acyclovir Cream，5%，是 Zovirax 的仿製藥，用於治療免疫功能低下的成人和 12 歲及以上青少年的複發性唇皰疹（冷敏感性）。宣布它已獲得美國食品和藥物管理局 (FDA) 的申請 (ANDA) 批准*。

單純皰疹病毒治療市場分為類型、藥物類型、分銷渠道和地區。 按類型分為單純皰疹病毒1型感染和單純皰疹病毒2型感染。 按藥物類型分為阿昔洛韋、伐昔洛韋和泛昔洛韋。 按銷售渠道劃分，它分為醫院藥房、藥店和零售藥房以及在線供應商。 按地區劃分，北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、意大利、西班牙、歐洲其他地區）、亞太地區（日本、中國、澳大利亞、印度、韓國、亞太地區其他地區），亞洲 它在太平洋地區（巴西、阿拉伯、澳大利亞、韓國、亞洲其他地區）進行了分析。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 頂級影響因子
    • 頂級投資基金
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手的實力
  • 市場動態
    • 司機
      • 單純皰疹病毒 (HSV) 感染率上升
      • 提高對單純皰疹病毒的認識
    • 約束因素
      • 圍繞單純皰疹病毒的恥辱
    • 機會
      • 增加研發活動
      • 新興經濟體的高增長潛力
  • 分析 COVID-19 對市場的影響

第 4 章單純皰疹病毒治療市場：按類型

  • 概覽
    • 市場規模和預測
  • 單純皰疹病毒 1 型感染
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 單純皰疹病毒 2 型感染
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 5 章單純皰疹病毒治療市場：按藥物類型分類

  • 概覽
    • 市場規模和預測
  • 阿昔洛韋
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 伐昔洛韋
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 泛昔洛韋
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 6 章單純皰疹病毒治療市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 7 章單純皰疹病毒治療市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
  • 歐洲
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
  • 拉美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模/預測：分佈
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道
      • LAMEA 的其餘部分
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類型
      • 市場規模和預測：按分銷渠道

第八章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第九章公司簡介

  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Fresenius SE and Co. KGaA
  • Amneal Pharmaceuticals LLC
  • Emcure Pharmaceuticals Limited
Product Code: A13199

The herpes simplex virus treatment market size valued for $1,724.27 million in 2021 and is estimated to reach $2,126.91 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.  

Herpes simplex virus (HSV) is a common viral infection that affects many people worldwide. There are two types of herpes simplex virus including type 1 (HSV-1) and type 2 (HSV-2). HSV-1 is usually associated with oral herpes, causing cold sores or fever blisters around the mouth. This type of herpes also causes genital herpes if it is transmitted through oral sex. HSV-2 is the most common cause of genital herpes, but it also causes oral herpes if it is transmitted through genital-to-oral contact. HSV can spread through sexual contact and virus also be transmitted in other ways. Herpes simplex virus treatment includes antiviral medications, topical creams or ointments, and home remedies to manage symptoms. The use of antiviral drugs has shown promising results in treating the disease.* 

The global herpes simplex virus treatment market is majorly driven by increase in the incidences of herpes viral infections. In addition, rise in R&D activities for herpes simplex virus and development of newer & advanced formulations, such as tablets and creams, are expected to fuel the market growth. For instance, AiCuris Anti-infective Cures AG is a German biopharmaceutical company that is developing a new antiviral drug (Pritelivir) for the treatment of HSV infections. This drug, Pritelivir, works by inhibiting the virus from replicating and has been shown to be effective in reducing viral shedding and the frequency of infections in clinical trials. Thus, rise in R&D activities for herpes simplex virus propels the market growth.* 

In contrast, limited awareness about the diseases such as sexually transmitted infections (STIs) and herpes virus in underdeveloped countries impedes the growth of the market. However, there is an increase in awareness of herpes infections, with rise in number of people are getting tested and diagnosed. This leads to increase in the demand for effective treatments in developed countries.*** 

Moreover, development and approvals of drugs for herpes simplex virus and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to drive the market growth during the forecast period. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.* 

The herpes simplex virus treatment market is segmented into type, drug type, distribution channel, and region. By type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. By drug type, the market is classified into acyclovir, valacyclovir, and famciclovir. By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).* 

Major key players that operate in the global herpes simplex virus treatment market are: Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the herpes simplex virus treatment market analysis from 2021 to 2031 to identify the prevailing herpes simplex virus treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the herpes simplex virus treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global herpes simplex virus treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By  Type

  • Herpes simplex virus-1 infection
  • Herpes simplex virus-2 infection

By  Drug type

  • Acyclovir
  • Valacyclovir
  • Famciclovir

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Viatris Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Fresenius SE and Co. KGaA
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Emcure Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of herpes simplex virus (HSV) infection
      • 3.4.1.2. Increase in awareness about herpes simplex virus
    • 3.4.2. Restraints
      • 3.4.2.1. Stigma associated with herpes simplex virus
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
      • 3.4.3.2. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Herpes simplex virus-1 infection
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Herpes simplex virus-2 infection
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Acyclovir
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Valacyclovir
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Famciclovir
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by  Type
    • 7.2.3. Market size and forecast, by  Drug type
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by  Type
      • 7.2.5.1.3. Market size and forecast, by  Drug type
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by  Type
      • 7.2.5.2.3. Market size and forecast, by  Drug type
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by  Type
      • 7.2.5.3.3. Market size and forecast, by  Drug type
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by  Type
    • 7.3.3. Market size and forecast, by  Drug type
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by  Type
      • 7.3.5.1.3. Market size and forecast, by  Drug type
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by  Type
      • 7.3.5.2.3. Market size and forecast, by  Drug type
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by  Type
      • 7.3.5.3.3. Market size and forecast, by  Drug type
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by  Type
      • 7.3.5.4.3. Market size and forecast, by  Drug type
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by  Type
      • 7.3.5.5.3. Market size and forecast, by  Drug type
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by  Type
      • 7.3.5.6.3. Market size and forecast, by  Drug type
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by  Type
    • 7.4.3. Market size and forecast, by  Drug type
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by  Type
      • 7.4.5.1.3. Market size and forecast, by  Drug type
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by  Type
      • 7.4.5.2.3. Market size and forecast, by  Drug type
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by  Type
      • 7.4.5.3.3. Market size and forecast, by  Drug type
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by  Type
      • 7.4.5.4.3. Market size and forecast, by  Drug type
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by  Type
      • 7.4.5.5.3. Market size and forecast, by  Drug type
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by  Type
      • 7.4.5.6.3. Market size and forecast, by  Drug type
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by  Type
    • 7.5.3. Market size and forecast, by  Drug type
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by  Type
      • 7.5.5.1.3. Market size and forecast, by  Drug type
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by  Type
      • 7.5.5.2.3. Market size and forecast, by  Drug type
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by  Type
      • 7.5.5.3.3. Market size and forecast, by  Drug type
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by  Type
      • 7.5.5.4.3. Market size and forecast, by  Drug type
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. GlaxoSmithKline plc
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Glenmark Pharmaceuticals Limited
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Pfizer Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Viatris Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Fresenius SE and Co. KGaA
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Amneal Pharmaceuticals LLC
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Emcure Pharmaceuticals Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 02. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 05. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 09. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 18. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 19. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 21. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 22. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 23. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 37. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 38. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 40. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 41. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 45. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 56. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 57. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 59. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 60. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 74. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 87. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 88. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 90. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 91. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 92. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 94. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 95. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 96. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 97. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 106. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 107. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 108. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 109. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 110. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 111. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 112. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 113. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 114. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES
  • TABLE 115. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 116. FRESENIUS SE AND CO. KGAA: PRODUCT SEGMENTS
  • TABLE 117. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 118. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 119. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 120. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 121. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 122. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 123. EMCURE PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 124. EMCURE PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 125. EMCURE PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 126. EMCURE PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN HERPES SIMPLEX VIRUS TREATMENT MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALHERPES SIMPLEX VIRUS TREATMENT MARKET
  • FIGURE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY COUNTRY 2021-2031(%)
  • FIGURE 13. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 17. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. HERPES SIMPLEX VIRUS TREATMENT MARKET BY REGION, 2021
  • FIGURE 22. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: HERPES SIMPLEX VIRUS TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2021
  • FIGURE 48. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 53. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. FRESENIUS SE AND CO. KGAA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 65. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. EMCURE PHARMACEUTICALS LIMITED: NET REVENUE, 2018-2020 ($MILLION)
  • FIGURE 70. EMCURE PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2020 (%)